Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report)'s share price shot up 5.1% on Tuesday . The stock traded as high as $3.98 and last traded at $3.90. 216,909 shares traded hands during trading, a decline of 37% from the average session volume of 345,457 shares. The stock had previously closed at $3.71.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "neutral" rating and set a $3.00 target price on shares of Kodiak Sciences in a research report on Monday, March 31st.
Read Our Latest Stock Report on KOD
Kodiak Sciences Stock Performance
The firm's 50-day moving average price is $3.83 and its two-hundred day moving average price is $4.75. The firm has a market capitalization of $230.84 million, a price-to-earnings ratio of -1.21 and a beta of 2.28.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). As a group, equities research analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current year.
Hedge Funds Weigh In On Kodiak Sciences
Institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE lifted its holdings in Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after purchasing an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Kodiak Sciences in the first quarter worth about $28,000. PNC Financial Services Group Inc. raised its stake in shares of Kodiak Sciences by 1,501.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock worth $32,000 after acquiring an additional 2,988 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Kodiak Sciences in the first quarter worth about $49,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Kodiak Sciences by 729.9% in the first quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after acquiring an additional 18,504 shares during the last quarter. 89.06% of the stock is owned by institutional investors.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Read More
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
